Susquehanna International Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$470M Sell
607,800
-2,700
-0.4% -$2.07M 0.05% 278
2025
Q4
$471M Sell
610,500
-47,800
-7% -$32.5M 0.05% 273
2025
Q3
$370M Sell
658,300
-62,000
-9% -$35.1M 0.04% 341
2025
Q2
$378M Buy
720,300
+193,300
+37% +$108M 0.05% 274
2025
Q1
$334M Buy
527,000
+133,500
+34% +$91.8M 0.06% 270
2024
Q4
$280M Sell
393,500
-106,600
-21% -$89.5M 0.04% 329
2024
Q3
$526M Buy
500,100
+164,000
+49% +$183M 0.09% 180
2024
Q2
$353M Sell
336,100
-47,600
-12% -$46.1M 0.07% 219
2024
Q1
$369M Sell
383,700
-191,300
-33% -$182M 0.06% 241
2023
Q4
$505M Sell
575,000
-5,300
-0.9% -$4.36M 0.1% 166
2023
Q3
$478M Sell
580,300
-246,900
-30% -$194M 0.1% 140
2023
Q2
$594M Sell
827,200
-193,100
-19% -$149M 0.12% 107
2023
Q1
$838M Buy
1,020,300
+377,900
+59% +$285M 0.18% 75
2022
Q4
$463M Sell
642,400
-43,500
-6% -$32.1M 0.12% 138
2022
Q3
$472M Buy
685,900
+241,500
+54% +$152M 0.12% 124
2022
Q2
$263M Buy
444,400
+10,600
+2% +$6.89M 0.07% 237
2022
Q1
$303M Sell
433,800
-283,900
-40% -$180M 0.05% 286
2021
Q4
$453M Sell
717,700
-225,200
-24% -$138M 0.07% 229
2021
Q3
$571M Sell
942,900
-159,900
-14% -$99.3M 0.08% 201
2021
Q2
$616M Sell
1,102,800
-194,000
-15% -$98.3M 0.09% 186
2021
Q1
$614M Buy
1,296,800
+48,600
+4% +$23.7M 0.1% 159
2020
Q4
$603M Buy
1,248,200
+521,000
+72% +$281M 0.1% 147
2020
Q3
$407M Buy
727,200
+21,400
+3% +$13M 0.08% 184
2020
Q2
$440M Sell
705,800
-20,800
-3% -$11.8M 0.11% 150
2020
Q1
$355M Buy
726,600
+35,300
+5% +$14.6M 0.11% 144
2019
Q4
$260M Buy
691,300
+84,200
+14% +$28.3M 0.07% 216
2019
Q3
$168M Buy
607,100
+124,200
+26% +$36.8M 0.06% 280
2019
Q2
$151M Sell
482,900
-78,700
-14% -$26.2M 0.05% 294
2019
Q1
$231M Sell
561,600
-300,100
-35% -$124M 0.09% 171
2018
Q4
$322M Buy
861,700
+35,400
+4% +$13M 0.13% 128
2018
Q3
$334M Buy
826,300
+112,200
+16% +$42.7M 0.11% 140
2018
Q2
$246M Buy
714,100
+53,700
+8% +$16.8M 0.08% 196
2018
Q1
$227M Sell
660,400
-486,400
-42% -$169M 0.08% 195
2017
Q4
$431M Sell
1,146,800
-65,600
-5% -$26.6M 0.15% 96
2017
Q3
$542M Buy
1,212,400
+59,200
+5% +$28.2M 0.21% 66
2017
Q2
$566M Buy
1,153,200
+346,900
+43% +$152M 0.25% 54
2017
Q1
$312M Buy
806,300
+189,600
+31% +$70.3M 0.16% 102
2016
Q4
$226M Sell
616,700
-23,000
-4% -$8.75M 0.11% 147
2016
Q3
$257M Sell
639,700
-132,400
-17% -$53.1M 0.12% 126
2016
Q2
$270M Buy
772,100
+144,100
+23% +$55.5M 0.14% 113
2016
Q1
$226M Sell
628,000
-276,000
-31% -$114M 0.12% 126
2015
Q4
$491M Buy
904,000
+130,700
+17% +$70.8M 0.23% 64
2015
Q3
$360M Sell
773,300
-35,700
-4% -$19.2M 0.16% 103
2015
Q2
$413M Buy
809,000
+15,300
+2% +$7.47M 0.18% 77
2015
Q1
$358M Sell
793,700
-48,900
-6% -$20.7M 0.16% 92
2014
Q4
$346M Buy
842,600
+207,800
+33% +$81.7M 0.14% 130
2014
Q3
$229M Sell
634,800
-58,600
-8% -$19.6M 0.09% 186
2014
Q2
$196M Sell
693,400
-73,900
-10% -$21.9M 0.08% 192
2014
Q1
$230M Buy
767,300
+165,300
+27% +$50.9M 0.11% 151
2013
Q4
$166M Buy
602,000
+226,800
+60% +$65.2M 0.08% 208
2013
Q3
$117M Buy
375,200
+7,600
+2% +$2M 0.06% 263
2013
Q2
$82.7M Buy
+367,600
New +$85.6M 0.05% 328

Other funds holding REGN

Susquehanna International Group's REGN Position: Q1 2026 in Review

Susquehanna International Group reduced its Regeneron Pharmaceuticals (REGN) stake by 67% in Q1 2026, selling an estimated $47.3M and leaving 30,620 shares worth $23.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

Susquehanna International Group first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $344M in Q4 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Susquehanna International Group held 30,620 shares of Regeneron Pharmaceuticals worth $23.7M as of Q1 2026.
  • Susquehanna International Group sold 61,841 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $47.3M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #2017 holding.
  • Susquehanna International Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • Susquehanna International Group's Regeneron Pharmaceuticals position peaked at $344M in Q4 2020.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.